Shanghai Shengqi Medical Technology Co., Ltd. - Leading Chinese Innovative Cardiovascular Interventi

Key Milestones (2024–2026):
   In April 2026, the company's self-developed SQ-Kyrin-M transcatheter mitral valve clip system received NMPA innovative product approval (registration no. 国械注准20263130777), becoming one of the few domestically developed transcatheter edge-to-edge repair systems in China. In June 2025, the PRipper peripheral cutting balloon received NMPA approval, the first domestic cutting balloon specifically for peripheral large vessels (5–8 mm). In August 2025, the SQ-Windfred peripheral vascular embolization coil was approved. In July 2025, the company entered a strategic partnership with Tonren Medical to advance heart failure treatment solutions.

Company Profile (Updated April 2026)

Shanghai Shengqi Medical Technology Co., Ltd. is a privately held innovative medical device company headquartered at No. 19 Building, 315 Qingda Road, Zhangjiang Science City, Pudong New Area, Shanghai, china. Founded in September 2014 by Dai Zhihao, a veteran with over 20 years of experience in the cardiovascular medical device industry, the company is dedicated to the research, development, manufacturing, and sales of high-value interventional consumAbles for cardiovascular and structural heart disease treatment.

The company operates a fully integrated R&D and manufacturing facility equipped with precision automated processing equipment, modern laboratories, and a Class 10,000 cleanroom compliant with national standards for Class III sterile medical product production. Shengqi Medical has established extensive clinical partnerships with top-tier Chinese hospitals including Ruijin Hospital, Zhongshan Hospital, and Beijing Anzhen Hospital. The company also maintains a strategic distribution partnership with MicroPort Scientific Corporation to accelerate market penetration.

Development History:

- 2014.09: Founded in Shanghai Zhangjiang High-Tech Park by Dai Zhihao, who previously held positions at Medtronic, Boston Scientific, MicroPort, and Weike Medical

- 2017.12: Established an independent R&D center dedicated to cardiovascular interventional device development

- 2019.12: Obtained NMPA registration for the swide QiJi drug-coated coronary balloon catheter (国械注准20193031052), becoming the second domestic company to receive drug-coated balloon approval in China

- 2020: Entered into channel cooperation with MicroPort to leverage MicroPort's distribution network for nationwide market expansion

- 2020.08: Completed Series C financing of several hundred million RMB, co-led by Hillhouse Venture Capital and Jifeng Capital, with continued support from SanZheng Health Investment and XingZe Capital

- 2020.12: Drug-coated balloon catheter selected into the Shanghai Municipal Innovative Product Recommendation Catalog

- 2021.07: Drug-coated balloon catheter recognized as a Shanghai High-Tech ACHievement Transformation Project

- 2021.08: SQ-Kyrin transcatheter mitral valve clip and steerable guiding catheter entered the NMPA Innovative Medical Device Special Review Program (green channel)

- 2022.01: SQ-WindRider QiYi detachable fibered coil embolization system received NMPA approval — the first domestically developed detachable fibered coil system for peripheral vascular use

- 2024.09: QiRui CRipper cutting balloon system received NMPA approval for coronary indications

- 2025.03: QiChuan SQ-Surgipath transjugular intrahepatic puncture device received NMPA approval; anti-embolism cerebral protection device entered the NMPA innovative device review program

- 2025.06: QiLi PRipper peripheral cutting balloon received NMPA approval (国械注准20253031104) — the first domestic cutting balloon for peripheral large vessels (5–8 mm)

- 2025.07: Entered strategic partnership with Tonren Medical to integrate artificial heart and ultrafiltration technology for comprehensive heart failure treatment solutions

- 2025.08: SQ-Windfred peripheral vascular embolization coil (spiral and cone types) received NMPA approval

- 2026.04: SQ-Kyrin-M transcatheter mitral valve clip system received NMPA innovative product approval (国械注准20263130777) for degenerative mitral regurgitation (MR≥3+) in high-surgical-risk patients

Core Mission: To innovate and develop high-quality cardiac and vascular interventional products that provide comprehensive treatment solutions for cardiovascular diseases, meeting the Rapidly growing healthcare demands of the Chinese market and benefiting patients worldwide.

Core Products & Business Scope

Cardiovascular Intervention

- swide QiJi Drug-Coated Coronary Balloon Catheter: Uses paclitaxel as the therapeutic drug with proprietary coating technology; indicated for coronary in-stent restenosis; deployed in over 1,100 hospitals nationwide; features "coats well, releases cleanly, stays effective" technology

- QiRui CRipper Coronary Cutting Balloon System: Approved September 2024 for treating atherosclerotic plaque in coronary arteries requiring cutting intervention

Peripheral Vascular Intervention

- QiLi PRipper Peripheral Cutting Balloon: First domestic cutting balloon for peripheral large vessels (5–8 mm diameter); indicated for iliac, femoral, popliteal, and renal artery lesions, as well as autologous or prosthetic arteriovenous dialysis fistula obstructive lesions

- SQ-Windfred Peripheral Vascular Embolization Coil: Spiral and cone configurations for embolization of peripheral aneurysms, arteriovenous malformations, and arteriovenous fistulas

- QiChuan SQ-Surgipath Transjugular Intrahepatic Puncture Device: For transjugular intrahepatic portosystemic shunt (TIPS) procedures to reduce portal hypertension

Neurovascular Intervention

- SQ-WindRider QiYi Detachable Fibered Coil Embolization System: First domestic detachable fibered coil for peripheral vascular embolization; features flexible detachment, stable basket formation, and dense embolization; applicable to vascular surgery, interventional radiology, hepatobiliary surgery, general surgery, oncology, and gastroenterology

Structural Heart Disease

- SQ-Kyrin-M Transcatheter Mitral Valve Clip System: NMPA-approved innovative product (April 2026); consists of mitral valve clip, delivery system, and guiding system; enables independent leaflet capture and multi-directional steering; indicated for high-surgical-risk patients with degenerative mitral regurgitation (MR≥3+)

- Left Atrial Appendage Occluder System: Under clinical development

- Mitral Valve Repair/Replacement Products: Under development

Heart Failure Management (Via Subsidiary)

- Beijing HartCare Medical Technology Co., Ltd.: Strategic investment by Shengqi Medical in 2020; China's first developer of heart failure ultrafiltration treatment devices; the heart failure ultrafiltration dehydration device received NMPA approval in 2017

Regulatory & Intellectual Property

- NMPA Approvals: Multiple Class III medical device registrations including drug-coated balloon, cutting balloon systems, embolization coils, transjugular puncture device, and transcatheter mitral valve clip

- Innovative Device Channel: Transcatheter mitral valve clip system entered the NMPA Innovative Medical Device Special Review Program in August 2021; anti-embolism cerebral protection device entered in March 2025

- Patents: 136 patents, 155 trademarks, and 3 copyrights as of 2026

- Certifications: National High-Tech Enterprise, Specialized and Innovative SME, Enterprise Technology Center (Shanghai municipal level — rated "Good" in 2025 evaluation), Technology-Advanced Service Enterprise, Innovative SME

Financial Performance & Funding

Funding History

- Series C (August 2020): Several hundred million RMB; co-led by Hillhouse Venture Capital and Jifeng Capital; existing investors SanZheng Health Investment and XingZe Capital continued participation; DianShi Capital served as exclusive financial advisor

- Key Investors: Hillhouse Venture Capital, Jifeng Capital, SanZheng Health Investment, XingZe Capital

Company Overview

Corporate Information

Legal Name: Shanghai Shengqi Medical Technology Co., Ltd.

Founded: September 9, 2014

Headquarters: No. 19 Building, 315 Qingda Road, Zhangjiang Science City, Pudong New Area, Shanghai 201203, China

Registered Capital: RMB 397,727,274 (approximately $54.8 million)

Paid-in Capital: RMB 397,727,274

Unified Social Credit Code: 913101153124932461

Legal Representative: Wang Sen

Company Type: Limited Liability Company (Hong Kong, Macao, Taiwan investment, non-sole proprietorship)

Industry: Medical Devices / High-Value Interventional Consumables

Employees: ~327–400

Website: www.shengqi.com.cn

Leadership Team

Founder & Chairman: Dai Zhihao

- Graduated from Shanghai Medical University (now Fudan University) School of Public Health in 1993; held positions at Medtronic, Boston Scientific, MicroPort, and Weike Medical; first entrepreneurial venture in 2006 in cardiovascular product distribution; founded Shengqi Medical in 2014

Legal Representative & Director: Wang Sen

- Joined the company in December 2014 as one of the earliest employees; previously served as R&D technical leader

Board Members (as of 2026): Chen Gang, Sheng Li, Zhou Guolei, Dai Zhihao, Chen Xinxing, Sheng Wei, among others

Strategic Partnerships

- MicroPort Scientific Corporation: Channel cooperation agreement leveraging MicroPort's nationwide distribution network for drug-coated balloon market expansion

- Tonren Medical: Strategic partnership (July 2025) integrating Tonren's CH-VAD left ventricular assist system with Shengqi's heart failure ultrafiltration technology to build comprehensive heart failure treatment solutions

- Beijing HartCare Medical Technology: Strategic investment (2020); heart failure ultrafiltration device developer

Competitive Landscape

Key Competitors

- Medtronic, Stryker: Global leaders dominating approximately 79% of the neurovascular intervention market

- B. Braun, Eurocor, Biotronik: International competitors in drug-coated balloon and peripheral vascular markets

- Lepu Medical, Wego Medical: Domestic competitors in cardiovascular interventional devices

- Peijia Medical, Neovas Medical: Domestic competitors in transcatheter valve repair

Competitive Advantages

- Comprehensive Portfolio: One of the few domestic companies with products spanning cardiovascular, peripheral, neurovascular, and structural heart disease

- Innovation Pipeline: 32+ products in development, all independently developed with full intellectual property rights

- Regulatory Track Record: Multiple NMPA approvals including innovative product designation for mitral valve clip system

- Clinical Validation: Products validated through clinical trials at 11+ top-tier Chinese hospitals

- Strategic Distribution: Partnership with MicroPort provides access to extensive hospital networks

- Cost Advantage: Domestic manufacturing enabling competitive pricing compared to imported alternatives (e.g., mitral valve clip priced ~200,000 RMB vs. imported ~300,000 RMB)

2026 Strategic Outlook

- Mitral Valve Clip Commercialization: Launch and scale the SQ-Kyrin-M transcatheter mitral valve clip system following NMPA innovative product approval

- Product Pipeline Advancement: Advance left atrial appendage occluder, mitral valve repair/replacement, and cerebral protection devices through clinical trials and regulatory approval

- Market Expansion: Continue expanding hospital coverage beyond 1,100+ current sites for drug-coated balloon and cutting balloon products

- Heart Failure Ecosystem: Deepen collaboration with Tonren Medical and HartCare to build integrated heart failure treatment solutions

- International Expansion: Position products for global market entry and participate in international competition

Contact Information

China Headquarters

Address: No. 19 Building, 315 Qingda Road, Zhangjiang Science City, Pudong New Area, Shanghai, China

Phone: 021-3130****

Website: www.shengqi.com.cn

Keywords: Shengqi Medical, Shanghai Shengqi, drug-coated balloon, cutting balloon, mitral valve clip, transcatheter mitral valve repair, left atrial appendage occluder, embolization coil, peripheral vascular intervention, neurovascular intervention, structural heart disease, cardiovascular intervention, NMPA, innovative medical device, Zhangjiang Science City, Dai Zhihao, Wang Sen, Hillhouse Venture Capital, Jifeng Capital, MicroPort, Tonren Medical, heart failure, ultrafiltration